Medivation Shares Doubled: What You Need to Know (MDVN)

Medivation Shares Doubled: What You Need to Know

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Medivation (Nasdaq: MDVN ) have more than doubled today, up by as much as an astronomical 135%, after the company announced its prostate cancer drug has proven effective.

So what: The biotech company announced that a phase 3 clinical trial showed that its drug candidate MDV3100 successfully met the study's pre-specified interim efficacy stopping criteria. The drug demonstrated a clinically meaningful and statistically significant improvement in overall survival compared to placebo.

Now what: MDV3100 showed a median overall survival advantage of 4.8 months and provided a 37% reduction in risk of death. Medivation is looking to meet with U.S. regulators early next year to discuss filing for regulatory approval, with analysts expecting approval in early 2013 that could promise annual revenue north of $1 billion. The news is also contributing to a sharp sell-off in rival Dendreon (Nasdaq: DNDN ) , which offers prostate cancer drug Provenge that has been facing sales headwinds.

Interested in more info on Medivation? Add it to your watchlist by clicking here.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Fool contributor Evan Niu holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.